Drug Trial Radar · NCT06816992
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
76
Planned (sponsor's estimate)
Start
Feb 27, 2025
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- ORIC PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Janssen Research & Development, LLC
- First posted
- Feb 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.
Conditions
- Solid Tumors
- EGFR Exon 20 Insertion Mutations
- NSCLC
- EGFR-mutated NSCLC
Interventions
ORIC-114 Dose 1 + amivantamabDrug
ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
ORIC-114 Dose 2 + amivantamabDrug
ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
ORIC-114 Dose 3 + amivantamabDrug
ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D)Time frame: 12 months
- Objective response rate (ORR)Time frame: 12 months
- Duration of response (DOR)Time frame: 12 months
- Progression-free survival (PFS)Time frame: 12 months
Locations
4 sites in 3 countries. Site status is shown where the registry gives one.
NYU Langone Health
New York, New York · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Not yet recruiting
The Princess Margaret Hospital
Toronto, Ontario, Canada · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.